FDA grants accelerated approval of Gardasil (HPV vaccine) for prevention of oropharyngeal and other head and neck cancers

The indication is for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. Continued approval is contingent on verification of clinical benefit in a confirmatory trial (currently underway).

Source:

PharmaTimes